1)日本婦人科腫瘍学会(編) : 子宮体がん治療ガイドライン2023年版,第5版.pp160-175,金原出版,2023
2)Kurman RJ, et al : Evaluation of criteria for distinguishing atypical endometrial hyperplasia. Cancer 49 : 2547-2559, 1982
3)Dunton CJ, et al : Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer. Am J Obstet Gynecol 174 : 1518-1521, 1996
4)Yoshimura T, et al : Clinical usefulness of endometrial cytology in determining the therapeutic effect of fertility preserving therapy. Acta Cytol 66 : 106-113, 2022
5)Koskas M, et al : Prognostic factors of oncolgic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma : systematic review and meta-analysis. Fertil Steril 101 : 785-794, 2014
6)Gallos ID, et al : Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia : a systematic review and metaanalysis. Am J Obstet Gynecol 207 : 266.e1-266.e12, 2012
7)Yamagami W, et al : Is repeated high-dose medroxyprogesterone acetate(MPA)therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? J Gynecol Oncol 29 : e21, 2018
8)National Comprehensive Cancer Network : NCCN Guidelines, Uterine Neoplasm, ver 2. 2024(2024年5月2日閲覧). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473
9)Concin N, et al : ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31 : 12-39, 2021
10)Park JY, et al : Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol 129 : 7-11, 2013
11)Murakami I, et al : Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer : a systematic literature review. J Gynecol Oncol 34 : e49, 2023
12)Sakai K,et al : A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate(MPA)therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial hyperplasia : Japanese Gynecologic Oncology Group study(JGOG2051/KGOG2031, REMPA trial). J Gynecol Oncol 35 : e106, 2024